Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Phase II oncology trials: let's be positive.

Literature DB >> 16115898

Phase II oncology trials: let's be positive.

Mark J Ratain.

Abstract

Mesh：

Year: 2005 PMID： 16115898 DOI： 10.1158/1078-0432.CCR-05-1046

Source DB: PubMed Journal: Clin Cancer Res ISSN： 1078-0432 Impact factor: 12.531

Keyword Cloud
Cited

× No keyword cloud information.

14 in total

Review 1. Imaging radiation response in tumor and normal tissue.

Authors: Marjan Rafat; Rehan Ali; Edward E Graves
Journal: Am J Nucl Med Mol Imaging Date: 2015-06-15

2. Recommended changes to oncology clinical trial design: revolution or evolution?

Authors: Mark J Ratain; Rachel W Humphrey; Gary B Gordon; Gwen Fyfe; Peter C Adamson; Thomas R Fleming; Walter M Stadler; Donald A Berry; Carl C Peck
Journal: Eur J Cancer Date: 2007-11-05 Impact factor: 9.162

3. Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors: Daniel V T Catenacci; Niall C Tebbutt; Irina Davidenko; André M Murad; Salah-Eddin Al-Batran; David H Ilson; Sergei Tjulandin; Evengy Gotovkin; Boguslawa Karaszewska; Igor Bondarenko; Mohamedtaki A Tejani; Anghel A Udrea; Mustapha Tehfe; Ferdinando De Vita; Cheryl Turkington; Rui Tang; Agnes Ang; Yilong Zhang; Tien Hoang; Roger Sidhu; David Cunningham
Journal: Lancet Oncol Date: 2017-09-25 Impact factor: 41.316

Review 4. Monitoring chemotherapy and radiotherapy of solid tumors.

Authors: Wolfgang A Weber; Hinrich Wieder
Journal: Eur J Nucl Med Mol Imaging Date: 2006-07 Impact factor: 9.236

5. Exposure-response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection.

Authors: Jian-Feng Lu; Erik Rasmussen; Beth Y Karlan; Ignace B Vergote; Lynn Navale; Mita Kuchimanchi; Rebeca Melara; Daniel E Stepan; David M Weinreich; Yu-Nien Sun
Journal: Cancer Chemother Pharmacol Date: 2012-01-01 Impact factor: 3.333

Phase II oncology trials: let's be positive.

Review 1. Imaging radiation response in tumor and normal tissue.

2. Recommended changes to oncology clinical trial design: revolution or evolution?

3. Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial.

Review 4. Monitoring chemotherapy and radiotherapy of solid tumors.

5. Exposure-response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection.

6. Clinical trials in the era of personalized oncology.

Review 7. Prostate cancer as a model for tumour immunotherapy.

8. Automated tracking of quantitative assessments of tumor burden in clinical trials.

9. Validation of novel imaging methodologies for use as cancer clinical trial end-points.

10. Rational Clinical Experiment: Assessing Prior Probability and Its Impact on the Success of Phase II Clinical Trials.